AMENDMENTS TO THE CLAIMS:

Please amend claims 1, 2, 6, 7, 9-11, 13-18, 20-24, 26-35, 39 and 41, and add new claim 42 as follows.

1. (Currently Amended) A method for establishing a diagnosis of a subtype of B-cell chronic lymphocytic leukaemia (B-CLL) in ~~a~~ an individual comprising detecting the presence or absence of at least one expression product, wherein said at least one expression product ~~comprise a~~ comprises at least one nucleotide sequence selected from the group consisting of ~~SEQ ID~~ SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17 and SEQ ID No:18 in a biological sample isolated from the individual.

2. (Currently Amended) A method for establishing the prognosis of B-CLL in a individual comprising detecting the presence or absence of at least one expression product, wherein said at least one expression product ~~comprise a~~ comprises at least one nucleotide sequence selected from the group consisting of ~~SEQ ID~~ SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17 and SEQ ID No:18 in a biological sample isolated from the individual.

3. (Original) A method for determining whether an individual has a B-CLL sub-type with poor prognosis, the method comprising determining the level of an expression product which comprise a nucleotide sequence selected from the group consisting of SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17 and SEQ ID No:18 of said individual, and indicating the individual as having a B-CLL sub-type with poor prognosis if the level of the expression product is at or beyond a discriminating value and indicating the individual as not having a B-CLL sub-type with poor prognosis if the level of the expression product is not at or beyond the discriminating value, the discriminating value being a value which has been determined by measuring the level of the expression product which comprise a nucleotide sequence selected from the group consisting of SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17 and SEQ ID No:18 in both a healthy control population and a population with known B-CLL sub-type with poor prognosis,

thereby determining said discriminating value which identifies the B-CLL sub-type population having a poor prognosis.

4. (Original) The method according to claim 3, wherein the individual is a member of an unselected population.

5. (Original) The method according claim 3, wherein the individual is a member of a population already identified as having a B-CLL sub-type with a poor prognosis.

6. (Currently Amended) The method according to ~~any of~~ claim~~s~~ 3-~~5~~, wherein the determination is performed at several time points at intervals as part of a monitoring of a cancer patient after or during the treatment for primary cancer.

7. (Currently Amended) The method according to ~~any of the preceding~~ claim~~s~~ 1, wherein the expression product is ~~a~~ at least one transcriptional product.

8. (Original) The method according to claim 7, wherein the at least one transcriptional product is selected from the group consisting of SEQ ID No 2, SEQ ID No 4, SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10 and SEQ ID No 11.

9. (Currently Amended) The method according to claim 7, wherein said at least one transcriptional product comprises a nucleotide sequence ~~selected from the group consisting of~~ ~~SEQ ID~~ SEQ ID ~~No:15~~ No 15.

10. (Currently Amended) The method according to claim 7, wherein said at least one transcriptional product comprises a nucleotide sequence ~~selected from the group consisting~~ of ~~SEQ ID~~ SEQ ID No:16.

11. (Currently Amended) The method according to claim 7, wherein said at least one transcriptional product comprises a nucleotide sequence spanning the junction between Exon-2 and Exon-3.

12. (Original) The method according to claim 11, wherein the nucleotide sequence spanning the junction between Exon-2 and Exon-3 is the last 20 nucleotides of the 3'-end of SEQ ID No:15 and the first 20 nucleotides of the 5'-end of SEQ ID No:16.

13. (Currently Amended) The method according to ~~any one of the preceding~~ claim~~s~~ 7, wherein the presence of at least one of the transcriptional

product(s) indicates that the individual has a subtype of B-CLL associated with a poor prognosis.

14. (Currently Amended) The method according to ~~any one of the preceding~~ claims ~~7~~ 7, wherein the presence or absence of the at least one transcriptional product~~(s)~~ is~~/are~~ determined by a method selected from the group consisting of a nucleic acid hybridisation based technique and a PCR based technique.

15. (Currently Amended) The method according to ~~any one of the preceding~~ claims ~~1~~ 1, wherein the biological sample ~~is~~ comprises a material selected from the group comprising blood, serum, plasma, urine, saliva, lymph node biopsy, bone marrow, spinal liquid, spleen biopsy, and liver biopsy.

16. (Currently Amended) ~~Use of~~ A method of treating B-CLL comprising administering to an individual in need thereof a compound capable of eliminating transcription of at least one expression product comprising a nucleotide sequence selected ~~form~~ from the group consisting of ~~SEQ ID~~ SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17 and SEQ ID No:18 ~~for the treatment of B-CLL~~.

17. (Currently Amended) ~~Use of~~ A method of preparing a medicament for the treatment of B-CLL comprising combining a pharmaceutically acceptable carrier with a compound capable of eliminating transcription of at least one transcriptional product comprising ~~a~~ at least one nucleotide sequence selected form the group consisting of ~~SEQ ID~~ SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17 and SEQ ID No:18 ~~for manufacture of a medicament for the treatment of B-CLL~~.

18. (Currently Amended) A method of treating B-CLL comprising administering to an individual in need thereof a compound capable of eliminating at least one ~~type of~~ transcriptional product, said transcriptional product comprising at least one nucleotide sequence selected from the group consisting of ~~SEQ ID~~ SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17 and SEQ ID No:18.

19. (Original) The method according to claim 18, wherein all types of the transcriptional product(s) are eliminated.

20. (Currently Amended) The method according to ~~any one of~~ claims 18 ~~or~~ ~~19~~, wherein the at least one transcriptional product is selected from the group consisting of SEQ ID No 2, SEQ ID No 4, SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10 and SEQ ID No 11.

21. (Currently Amended) The method according to ~~any one of~~ claims 18-~~20~~, wherein the elimination of the at least one transcriptional product is achieved by inhibiting the formation of the transcriptional product.

22. (Currently Amended) The method according to ~~any one of~~ claims 18-~~20~~, wherein the elimination of the at least one transcriptional product is achieved by destroying the transcriptional product.

23. (Currently Amended) The method according to claim 21, wherein the compound is a~~n~~ nucleotide capable of inhibiting the transcription of a nucleic acid sequence encoding any transcriptional product comprising a nucleotide sequence selected from the group consisting of ~~SEQ ID~~ SEQ ID SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17 and SEQ ID No:18.

24. (Currently Amended) The method according to claim 22, wherein the compound is a~~n~~ nucleotide capable of destroying any transcriptional product comprising a nucleotide sequence selected from the group consisting of SEQ ID ~~SEQ ID SEQ ID~~ No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17 and SEQ ID No:18.

25. (Original) The method according 24, wherein the nucleotide is an si-RNA.

26. (Currently Amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

i) an amino acid sequence of SEQ ID NO: 3,

ii) an amino acid sequence having at least 60% sequence identity compared to the full length sequence of SEQ ID NO:3, and

ii) a fragment of SEQ ID NO:3 having at least 60% sequence identity compared to the full length sequence of SEQ ID NO:3.

27. (Currently Amended) An isolated polypeptide according to claim 26, said polypeptide having interleukin or cytokine activity.

28. (Currently Amended) The isolated polypeptide according to ~~any one of~~ claims 26 ~~or 27~~, which folds as a 4-helical cytokine.

29. (Currently Amended) ~~Use of~~ A diagnostic method for diagnosing subtype of B-CLL comprising determining if an individual has an isolated polypeptide according to ~~any of claims~~ claim 26~~-28~~. ~~in a diagnostic method for a subtype of B-CLL having a poor prognosis~~.

30. (Currently Amended) The ~~use~~ method according to claim 29, wherein the diagnostic method is based on immunological assays~~, such as FACS analysis, western blotting, RIA, ELISA, immunohistochemistry etc~~.

31. (Currently Amended) ~~Use of~~ A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of an isolated polypeptide as defined in ~~any of the~~ claims 26~~-28 for the treatment of cancer~~.

32. (Currently Amended) ~~Use of~~ A method for preparing a medicament for the treatment of cancer, comprising combining a pharmaceutically acceptable carrier with an isolated polypeptide as defined in ~~any of the~~ claims 26~~-28~~ for the preparation of a medicament for the treatment of cancer.

33. (Currently Amended) ~~Use~~ A method for treating cancer according to claims 31 ~~or 32~~, wherein the cancer is B-CLL.

34. (Currently Amended) A method of immunisation of a patient in need thereof against B-CLL, wherein said immunisation generates an immune response in said patient which recognises ~~a~~ at least one translational product of SEQ ID No 2, SEQ ID No 4, SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10 and SEQ ID No 11.

35. (Currently Amended) A method for producing an antibody with specificity against an isolated polypeptide as defined in ~~any of the~~ claims 26 ~~to 28~~, said method comprising the steps of

i) providing a host organism,

ii) immunising said host organism with an isolated polypeptide as defined in ~~any of the~~ claims 26 ~~to 28~~, or transfecting said host organism with an expression vector capable of directing the

expression of an isolated polypeptide as defined in ~~any of the~~ claims 26 ~~to 28~~, and

iii) obtaining said antibody.

36. (Original) An antibody obtainable by the method of claim 35.

37. (Original) An isolated polynucleotide selected from the group consisting of:

i) a polynucleotide comprising SEQ ID NO:5

ii) a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID No 3,

iii) a polynucleotide, the complementary strand of which hybridises, under stringent conditions, with a polynucleotide as defined in any of i) and ii), and encodes a polypeptide, which has at least 60% sequence identity with the amino acid sequence of SEQ ID No 3,

iv) a polynucleotide which is degenerate to the polynucleotide of iii), and

v) the complementary strand of any such polynucleotide.

38. (Original) The isolated polynucleotide according to claim 37, comprising the nucleotide sequence selected from the group consisting of SEQ ID No:2, SEQ ID No:4, SEQ ID No:6, SEQ ID No:7, SEQ ID No:8, SEQ ID No:9, SEQ ID No:10 and SEQ ID No:11.

39. (Currently Amended) A diagnostic kit for *ex vivo* or *in situ* diagnosis of a subtype of B-cell chronic lymphocytic leukaemia (B-CLL) in ~~a~~ an individual, the kit comprising a detector molecule capable of detecting the presence or absence of at least one expression product, wherein said at least one expression product comprises a nucleotide sequence selected from the group consisting of ~~SEQ ID~~ SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17 and SEQ ID No:18 in a biological sample isolated from the individual.

40. (Original) A kit according to claim 39, wherein the detector molecule is a nucleotide.

41. (Currently Amended) A kit according to claim 40, wherein the nucleotide is capable of hybridising to a nucleotide sequence selected from the group

consisting of ~~SEQ ID~~ SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17 and SEQ ID No:18 under stringent condition.

42. (New) The method according to claim 30 wherein the immunological assays include one or more of FACS analysis, western blotting analysis, RIA, ELISA or immunohistochemistry.